Physician profile
Russell Proctor
NPI 1962511790
$2,451.02
in general payments reported to CMS, 2019-2025
23 companies · $90.34 in 2025
The $90.34 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $530 · 2021: $580 · 2022: $278 · 2023: $514 · 2024: $14.27 · 2025: $90.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.95 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $463.47 | 2019-2023 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $406.94 | 2019-2023 | Trelegy Ellipta |
| Insmed, INC. | $178.48 | 2019-2023 | Arikayce |
| Mylan Specialty L.P. | $161.45 | 2019-2023 | Yupelri |
| Philips North America LLC | $64.29 | 2023 | |
| Lilly USA, LLC | $48.43 | 2020-2023 | Reyvow, Emgality |
| Genentech USA, INC. | $39.95 | 2019 | |
| United Therapeutics Corporation | $36.84 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $36.31 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $35.18 | 2020-2021 | |
| Allergan, INC. | $32.70 | 2019-2020 | |
| Electromed, INC. | $32.37 | 2025 | Smartvest |
| Axsome Therapeutics, INC. | $25.70 | 2025 | Sunosi |
| Acadia Pharmaceuticals INC | $21.05 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.90 | 2023 | |
| Janssen Pharmaceuticals, INC | $16.76 | 2020 | |
| Harmony Biosciences LLC | $16.45 | 2021 | |
| Adamas Pharmaceuticals, INC. | $16.40 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.09 | 2019 | |
| Novo Nordisk INC | $13.67 | 2025 | Wegovy |
| Eisai INC. | $13.46 | 2020 | |
| Upsher-Smith Laboratories LLC | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.